BERNARD MAJOIE

Bernard Majoie stands as a towering figure in the landscape of European venture capital, particularly within the life sciences sector. His profound impact stems from his role as the co-founder and former Chief Executive Officer of the European Investment Fund (EIF), an institution pivotal in stimulating small and medium-sized enterprises (SMEs) across Europe. Through his leadership at the EIF, Majoie played a critical role in developing the continent's venture capital ecosystem, especially in high-growth, knowledge-based industries like biotechnology and healthcare.

His investment focus areas are primarily centered on life sciences, encompassing biotechnology, pharmaceuticals, medical devices, and broader healthcare innovation. Majoie's vision has consistently been to bridge the funding gap for innovative European companies, enabling them to translate groundbreaking research into commercial success and patient benefit. He has been a staunch advocate for strategic investments that not only yield financial returns but also contribute significantly to scientific advancement and economic growth within the European Union.

Bernard Majoie's career background is uniquely multidisciplinary, blending deep scientific expertise with astute financial acumen. Holding both an MD and a PhD, he began his professional journey in medical research, notably at the prestigious Pasteur Institute. This scientific foundation provided him with an unparalleled understanding of the intricacies and potential of biotech innovation. His transition into the world of finance and investment was marked by a commitment to leveraging capital to accelerate scientific progress. Beyond the EIF, Majoie has contributed his expertise to various boards and advisory roles within the biotech and venture capital communities, including a tenure as a Venture Partner at Sofinnova Partners, one of Europe's leading life sciences venture capital firms.

While the EIF primarily invests in venture capital funds rather than directly in companies, Bernard Majoie's strategic direction led to the indirect funding of countless successful European biotech ventures. His initiatives helped establish a robust framework for venture capital in Europe, fostering an environment where innovative companies could thrive. His influence is seen in the growth of numerous companies that have benefited from EIF-backed funds, contributing to significant advancements in areas from novel therapeutics to diagnostic tools. Majoie's legacy is defined by his pioneering spirit in creating financial instruments and platforms that have profoundly shaped the European life sciences investment landscape, making him a true architect of biotech innovation on the continent.